CEBPA and acute myeloid leukemia: AML patients with high CEBPA gene expression had a cumulative OS at 6 months 90.2%, while patients with low CEBPA gene expression had a cumulative OS at 6 months 13.6%, with statistically significant difference between the two patients’ group with P value <0.001.